MedTrace Logo

Aspirin Reload Before Percutaneous Coronary Intervention: Reperfusion Indexes Evaluation.

NCT01374698 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2013-05-14

No results posted yet for this study

Summary

This is a prospective, randomized study conducted in patients undergoing coronary revascularization procedures (PCI) through angioplasty. All patients who meet the eligibility criteria will be randomized to receive, before the procedure, an oral aspirin reload (325 mg) and to be re-evaluated at 60 minutes, 120 minutes, 6 hours, 48 hours, 5 and 30 day, 3 and 6 months.

Conditions

  • Coronary Arteriosclerosis

Interventions

DRUG

Aspirin

Aspirin 325 mg

Sponsors & Collaborators

  • University of Roma La Sapienza

    lead OTHER

Principal Investigators

  • Stefania Basili, MD · Sapienza-Univerity of Rome

  • Violi Francesco, Prof. · Sapienza

  • Gaetano Tanzilli, Prof. · Sapienza

  • Marcello Dominici, MD · Division of Cardiology, Department of Interventional Cardiology, Santa Maria University Hospital, Terni, Italy

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2011-09-30
Completion
2012-09-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01374698 on ClinicalTrials.gov